Page last updated: 2024-08-16

triazolam and scopolamine hydrobromide

triazolam has been researched along with scopolamine hydrobromide in 8 studies

Research

Studies (8)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (12.50)	18.2507
2000's	4 (50.00)	29.6817
2010's	3 (37.50)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Lombardo, F; Obach, RS; Waters, NJ	1
Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Kulkarni, SK; Shaji, AV	1
Griffiths, RR; Mintzer, MZ	1
Love, PL; Shannon, HE	1
Griffiths, RR; Kleykamp, BA; Mintzer, MZ	1

Reviews

1 review(s) available for triazolam and scopolamine hydrobromide

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

2 trial(s) available for triazolam and scopolamine hydrobromide

Article	Year
Acute dose-effects of scopolamine on false recognition. Psychopharmacology, 2001, Volume: 153, Issue:4 Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; GABA Modulators; Humans; Male; Middle Aged; Muscarinic Antagonists; Psychomotor Performance; Recognition, Psychology; Scopolamine; Triazolam	2001
Dose effects of triazolam and scopolamine on metamemory. Experimental and clinical psychopharmacology, 2010, Volume: 18, Issue:1 Topics: Adult; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Memory; Mental Recall; Psychomotor Performance; Scopolamine; Triazolam; Young Adult	2010

Other Studies

5 other study(ies) available for triazolam and scopolamine hydrobromide

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7 Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding	2008
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination. Journal of medicinal chemistry, 2010, Feb-11, Volume: 53, Issue:3 Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations	2010
Evidence of GABAergic modulation in melatonin-induced short-term memory deficits and food consumption. Methods and findings in experimental and clinical pharmacology, 1998, Volume: 20, Issue:4 Topics: Animals; Antioxidants; Diazepam; Eating; Female; Flumazenil; GABA Modulators; Latency Period, Psychological; Male; Maze Learning; Melatonin; Memory Disorders; Memory, Short-Term; Mice; Muscarinic Antagonists; Rats; Rats, Wistar; Receptors, GABA; Scopolamine; Triazolam	1998
Within-session repeated acquisition behavior in rats as a potential model of executive function. European journal of pharmacology, 2004, Sep-13, Volume: 498, Issue:1-3 Topics: Animals; Apomorphine; Behavior, Animal; Cognition; Conditioning, Operant; Dizocilpine Maleate; Dopamine Agonists; Dose-Response Relationship, Drug; Excitatory Amino Acid Antagonists; GABA Modulators; Male; Models, Animal; Motor Activity; Muscarinic Antagonists; Phencyclidine; Psychomotor Performance; Rats; Rats, Inbred F344; Scopolamine; Triazolam	2004